The hunt for a compound which inhibits the HIV-1 integrase had been painstakingly difficult. Integrase is essential for viral replication as it mediates the integration of the viral DNA genome into the host DNA resulting in the establishment of the permanent provirus. Persistent efforts have resulted in the discovery of Raltegravir (Isentress, MK-0518), the first integrase inhibitor approved by US Food and Drug Administration for the treatment in HIV-1 infected patients. Numerous clinical studies with raltegravir have found it to be safe and effective in treatment naïve as well as treatment experienced patients. Adverse events associated with raltegravir based therapy are milder compared to previously available regimens. Raltegravir is metabolized primarily via glucuronidation mediated by uridine diphosphate glucuronosyltransferase and has a favorable pharmacokinetics independent of age, gender, race, food, and drug-drug interactions. Within a short period of time of its introduction, raltegravir has been included as one of DHHS recommended preferred regimen for the treatment of HIV-1 infection in treatment naïve patients.
Introduction
With the approval of raltegravir for the treatment of HIV-1 in 2007, the HIV/AIDS patients have another drug in their armamentarium to increase their survival and improve the quality of life. According to the 2010 report of Joint United Nations Programme on HIV/AIDS (UNAIDS), there were nearly 33 million people infected with HIV-1 in 2009. This number is continuously increasing at a rate of ∼7000 new infections everyday resulting in approximately 2.6 million new infections in 2009. 1 Since the introduction of highly active antiretroviral therapy (HAART), HIV-1 infected patients have managed to maintain the quality of life and survive longer. However, HIV/AIDS remains incurable as none of these drugs eradicate the virus; rather just prevents viral replication. Due to the inevitable development of resistance to these drugs, search for inhibitors targeting novel viral or cellular targets has been an ongoing phenomenon. HIV-1 genome encodes for three viral enzymes, reverse transcriptase, protease, and integrase (IN), all essential for its replication. Several drugs have already been developed and approved for therapeutic use against reverse transcriptase and protease. Raltegravir belongs to a novel class of antiretroviral drugs as it inhibits the HIV-1 IN. Initially, raltegravir was approved for antiretroviral therapy (ART) in combination with other classes of drugs in treatment experienced patients. Later, its approved use was extended in ART naïve patients. Due to the absence of a IN homolog in human, inhibitors including raltegravir targeting IN possess lower toxicity and have better tolerability. Long term studies with raltegravir have proved it to be a safe and effective alternative to patients over the high toxicity associated with reverse transcriptase inhibitors and potential lipid profile changes in patients treated with protease inhibitors. This review discusses the findings from numerous clinical studies on the efficacy and safety of raltegravir primarily in treatment naïve patients.
Mechanism of Action
Raltegravir (Fig. 1 ), 2 developed by Merck & Co. is the first HIV-1 IN inhibitor approved by US Food and Drug Administration (FDA). Two other IN inhibitors, elvitegravir (GS-9137, JTK-303) 3 and S/GSK 1349572 (dolutegravir) 4, 5 are in the late stages of clinical trials. IN is essential for viral replication as it is responsible for integration of viral DNA into the host DNA. IN is formed by the proteolytic processing of the gag-pro-pol precursor. HIV-1 IN contains 288 amino acids (aa) and is composed of three structural domains. The N-terminal domain (1-50 aa) contains a histidine-histidine-cysteinecysteine (HHCC) motif that is involved in zinc binding and is associated with multimerization of IN. 6 The catalytic core domain (50-212 aa) contains the catalytic triad of three acidic residues D-D-E motif comprising aspartic acid (D64, D116) and glutamic acid (E152) responsible for coordinating the metal ions and forming the IN active site. 7, 8 The C-terminal domain (213-288 aa), which adopts a SH3-like fold binds both the viral DNA and host DNA. [9] [10] [11] During catalysis, IN first removes the terminal two nucleotides (GT) adjacent to the conserved CA motif from the 3′-end of the viral blunt-ended termini within the cytoplasmic preintegration complex in virus-infected cells leaving a recessed 3′-OH at both termini. In the next step, known as strand transfer, IN creates nicks on opposing strands of host DNA by a nucleophilic reaction using recessed 3′-OH ends and subsequent joining of the 3′-end of viral DNA into host DNA. Both of these reactions are separated temporally and occur in different cellular compartments. IN strand transfer inhibitors (STIs) including raltegravir inhibit the latter reaction and prevent the joining of viral DNA to the host DNA. STIs at the effective concentrations (IC 50 ) have minimal effect on 3′-OH processing activity of IN. 12, 13 Raltegravir blocks HIV-1 replication with a 95% inhibitory concentration (IC 95 ) of 31 nM in 50% normal human serum in vivo. 2, 14 The biochemical mechanisms of raltegravir inhibitory effects have been investigated in vitro. STIs including raltegravir do not bind IN, rather they bind to the IN-DNA complex, 15, 16 hence this class of inhibitors are also known as interfacial inhibitors. 17 Binding of raltegravir to the IN-DNA complex is dependent on presence of divalent metal ions at the IN active site. Raltegravir chelate the metal ions through its diketo group in the active site within the IN-DNA complex ( Fig. 1 ). This complex, termed synaptic complex, is a transient intermediate in the concerted integration pathway in vitro. It is formed by the juxtaposition of two viral long terminal repeat (LTR) ends by IN and in presence of a target DNA forms the concerted integration products analogous to integration in vivo. [18] [19] [20] Raltegravir and other STIs bind to and inactivate the synaptic complex, thereby preventing the binding of host target DNA thus inhibiting strand transfer. [19] [20] [21] Raltegravir inhibits concerted integration activity with an IC 50 value of ∼21 nM in vitro. 19 L-870,810, a sister compound of raltegravir which also contains an active diketo group has been shown to affect the structure of synaptic complex. L-870,810 binding within the synaptic complex moved the 5′-end of the non-transferred strand of U5 LTRs by more than 20 Å. 18 Detailed mechanistic information about mode of action of STIs came from recent crystallization studies of IN from prototype foamy virus (PFV). Despite only ∼20% sequence similarity between HIV-1 IN and PFV IN, the structures of individual domains in both INs are remarkably alike and share similar aa within the active site. PFV IN is also inhibited by HIV-1 IN STIs. 22 The crystal structure of PFV IN complexed with its cognate substrate provided crucial insights into IN-DNA interactions. 23, 24 The crystal structure of PFV IN-DNA complex soaked with raltegravir and elvitegravir promoted an understanding of their inhibitory mechanism. Binding of raltegravir into the active site within the IN-DNA complex displaced the reactive 3′-OH group by more than 6 Å. The halobenzyl group localizes in the binding pocket created by the displacement of the 3′-OH group of terminal adenosine on the viral DNA. 23 Inhibition by elvitegravir and other strand transfer inhibitors is similar to raltegravir. 23, 25 Attempts to crystallize the full-length HIV-1 IN alone or in complex with its DNA substrates have not yet been successful.
Metabolism and Pharmacokinetics
Raltegravir is metabolized via glucuronidation mediated primarily by uridine diphosphate glucuronosyltransferase (UGT)1A1 with minor contributions from UGT1A3 and UGT1A9. 26 The major function of UGT1A1 and other related family enzymes are to metabolize drugs as well as a number of endogenous and exogenous substances including steroids, hormones, and bilirubin. Glucuronidation of raltegravir results in the formation of raltegravir glucuronide. Metabolism and disposition of raltegravir was determined using a single 200 mg dose of potassium salt of [ 14 C]-raltegravir in healthy individuals. The 14 C was monitored up to 240 h post-dose. Peak plasma concentration (C max 4.94 µM) and radioactivity was observed within 1 h of dosing. After 24 h of dosing, the raltegravir and radioactivity were undetectable suggesting a rapid clearance. Most of the radioactivity was eliminated through urine and feces at 32% and 51%, respectively, resulting in a total recovery of 83%. Of the total radioactivity recovered in urine, 95% of was released within first 8 h of dosing. LC-MS/MS analysis combined with radiochromatogram of urine and feces revealed two peaks correlating with raltegravir and its glucuronide derivative. In urine, approximately 8%-11% of raltegravir was excreted unchanged and 23% of the dosage radioactivity was in form of raltegravir glucuronide. 26, 27 Raltegravir was the only peak observed in the fecal extracts. While in the plasma, 70% of the radioactivity was due to raltegravir and remaining in the form of its glucuronide derivative.
The pathway involved in raltegravir metabolism was established by in vitro studies. These studies utilized cDNAs expressing UGTs, human liver microsomes, and typical UGT1A1 substrates like bilirubin and β-estradiol acting as the inhibitors for raltegravir glucuronidation. Taken together, the in vitro studies confirmed that ∼70% of raltegravir given in the dose was metabolized by UGT1A1. 26 Metabolism of raltegravir is altered by the polymorphism present in UGT1A1. One of the common polymorphism associated with UGT1A1 contains TA repeat expansion (TA) 7 in the TATAA box of the gene (Gilbert's syndrome). 28 Individuals homozygous for the (TA) 7 allele, also known as UGTA1*28/*28 genotype, have higher serum bilirubin level because of the reduced UGT1A1 activity (∼30%), compared to normal healthy individuals. This group of individuals having reduced UGT1A1 activity constitutes ∼3%-10% of the general population. However, in a study involving 30 subjects to analyze the pharmacokinetics of raltegravir (single 400 mg dose) in UGT1A1*28/*28 genotype, the reduced UGT1A1 activity did not result in clinically significant differences compared to the control subjects. 29 The control arm of the study had 27 subjects containing normal length of TA repeats (TA) 6 (UGT1A1*1/*1). The time to maximum concentration (T max ) was remarkably similar (2.0 h) in both subject groups and the difference in half-life was not significant. However, reduced UGT1A1 activity in UGT1A1*28/*28 genotype subjects resulted in increased plasma raltegravir concentration (4.60 µmol/l) vs. 3.20 µmol/l in subjects having normal genotype (UGT1A1*1/*1). Concentration at the 12 h time point (C 12h ) after administration of raltegravir was 91% higher in subjects with UGT1A1*28/*28 genotype. However, the higher raltegravir concentration did not result in any unexpected adverse effects. This finding was consistent with several other reports suggesting no dose-related toxicities with raltegravir. 30, 31 In comparison to other antiretroviral drugs, raltegravir has fewer drug-drug interactions. Interactions of raltegravir with other antiretroviral drugs have been described in detail elsewhere. 32 UGT1A1 expression is altered by a wide variety of drugs eg, protease inhibitor atazanavir 33 and nonnucleoside reverse transcriptase inhibitor efavirenz 34 ( Table 1) . Rifampin is a broad potent inducer of UGT1A1 and other drug metabolizing enzymes like cytochrome P-450 (CYP) pathway. Rifampin reduces the effective raltegravir concentration. Rifampin is administered to HIV-1 infected individuals also diagnosed with tuberculosis (TB). TB is one of the leading causes of deaths in HIV-1 infected patients. Multiple studies have concluded that earlier initiation of ART in HIV-1 infected patients with tuberculosis leads to increased survival. [35] [36] [37] Pharmacokinetics of raltegravir (400 mg single dose) in combination with rifampin (600 mg once a day) in healthy individuals showed that the area under the concentration curve (AUC 0-∞ ) and C max for raltegravir was reduced 40% and 38%, respectively. 38 In patients undergoing treatment with rifampin, the recommended dosage of raltegravir is 800 mg twice daily. The higher dose of raltegravir compensates the effect of rifampin on AUC 0-12 , however, the C 12 remained largely unchanged probably due to the increased clearance caused by enhanced UGT1A1 activity resulting from rifampin exposure. In a clinical study involving four HIV-1 positive patients who had developed TB, raltegravir (800 mg twice daily) was given along with tenofovir/emtricitabine nearly two months after the beginning of TB treatment. At the end of TB treatment, all of the patients had undetectable level of HIV-1 RNA with no evidence of virological rebound. No significant adverse events due to the combined TB treatment and ART were reported. This study indicated that even though rifampin reduces the effective raltegravir concentration in plasma, raltegravir is still safe and effective in controlling HIV-1 replication in TB patients undergoing rifampin treatment. 39 Pharmacokinetic study of raltegravir (800 mg twice a day) in two HIV-2 patients (one with HIV-1/HIV-2 dual infection) treated concurrently with rifampin for TB suggested that AUC value 40 was as high as geometric mean value observed in phase II study with standard 400 mg twice a day dosage. 30 A phase II clinical trial (NCT00822315) ( Table 2) with treatment naïve HIV-1 infected patients receiving rifampin for TB, is underway to compare the efficacy and safety of two different doses of raltegravir (400 mg and 800 mg) and efavirenz in combination with tenofovir and lamivudine. The results from this study should help determine the appropriate dosage of raltegravir for patients undergoing rifampin treatment for TB.
ATP binding cassette (ABC) efflux transporter family and solute carrier uptake transporters have been implicated in transport of raltegravir as well as several other antiretroviral drugs. 41 Polymorphism in ABC efflux transporter family ABCB1 gene (3435C-T) coding for a P-glycoprotein (a transporter protein) results in ∼60% lower raltegravir plasma concentration. The median plasma raltegravir concentration in individuals with CT/TT genotype was 221 ng/ml [IQR 92-626] compared to 530 ng/ml [IQR 212-1066] in normal individuals with CC genotype. 42 However, Table 1 . FDA approved drugs for treatment in Hiv-1 infected patients.
Reverse transcriptase
Protease Integrase Fusion CCR5
NRTIs NNRTIs
Abacavir (ABC) Ziagen the viral response to raltegravir was not significantly affected by this polymorphism.
Pharmacokinetics of raltegravir in treatment naïve HIV-1 patients receiving different dosage of raltegravir (100, 200, 400 or 600 mg twice a day) suggested no apparent dose response with regard to its virological efficacy. 30 Mean trough raltegravir concentration (C 12h ) in each dosage group was higher than the in vitro IC 95 value of 33 nM. Mean values for C max and AUC 0-12h increased up to the 400 mg dose but were similar for the 400 and 600 mg regimens. 30 In a phase I multi-dose pharmacokinetic study in healthy individuals, trough levels (C 12 ) were more than 33 nM for raltegravir dosage levels 100 mg or higher. 27 Results from these two studies supports the recommended 400 mg twice a day dosage in patients as it will maintain the C 12 higher than the IC 95 value. AUC 0-∞ was found to be similar in male and female subjects given a single 400 mg dose of raltegravir. AUC was considered to be the most appropriate pharmacokinetic parameter for raltegravir to determine its clinical significance. In multiple studies, raltegravir followed a biphasic pharmacokinetics. At the recommended raltegravir dose 400 mg twice a day, the terminal elimination half-life is ∼9 h (7-12 h range) with shorter 1 h half-life in α-phase. 27, 31 Steady state is generally reached in 2 days. No major toxicities were reported with higher doses of raltegravir up to 1600 mg/day. Gender or the race (black vs. nonblack) of the patients had no significant effect on raltegravir pharmacokinetics. 43 There have been no studies to determine the pharmacokinetics or efficacy of raltegravir in pediatric HIV-1 patients. Pediatric formulations in the form of oral granules in suspension and chewable ethyl cellulose tablets given to healthy adult individuals (n = 12) had the similar pharmacokinetics as the marketed poloxamer tablet. 44 The individuals were given a single 400 mg dose of raltegravir in different formulations. Both pediatric formulations were well tolerated and had moderately higher AUC 0-∞ and C max compared to the tablet formulation.
No serious clinical adverse events were reported in this study. The individuals who took raltegravir along with a high fat diet led to an increase in C 12h , a reduction in C max and delay in T max , however, the AUC 0-∞ was not changed. 44 At present, raltegravir is not approved for pediatric use.
Safety and Efficacy in Clinical Studies
A list of key clinical studies with raltegravir in treatment naïve patients is given in Table 2 . Monotherapy with multiple doses of raltegravir in treatment naïve HIV-1 infected individuals for 10 days showed it to contain superior antiretroviral activity compared to the placebo. 30 The subject individuals had $5000 copies/ml viral RNA and CD4 cell count of greater than 100 cell/mm 3 . Raltegravir was administered twice a day at a fixed dose (100, 200 400 or 600 mg). Patients in each group treated with raltegravir showed at least 2-fold log reduction in HIV-1 RNA load. At least 50% of the subjects in each dosage group achieved viral RNA level ,400 copies/ml. STARTMRK is an ongoing phase III clinical trial (ClinicalTrials.gov identifier NCT00369941, Merck MK-0518 protocol 021) designed to compare the efficacy and safety of raltegravir in ART naïve HIV-1 patients. This study compared raltegravir against efavirenz, both in combination of tenofovir and emtricitabine ( Table 1 ). Raltegravir at 400 mg twice a day or the placebo was given at 12 h interval. Tenofovir (300 mg) and emtricitabine (200 mg), nucleoside reverse transcriptase inhibitors, were administered as a single dose of Truvada in the morning with food. Patients in the efavirenz arm were advised to take 600 mg dose (or placebo) on empty stomach at the bed time. The enrolled patients were $18 years old, had .5000 copies/ml of HIV-1 RNA with no evidence of resistance to efavirenz, tenofovir or emtricitabine. Patients were from broad demographics belonging to five continents and hence infected with HIV-1 subtype B as well as non-B clades. Patients were sub grouped on the basis of baseline HIV-1 RNA level (less than or more than 50,000 copies/ml), their Hepatitis B and Hepatitis C status. Results obtained at 156 week of the study suggested that raltegravir exhibited durable antiretroviral response that was non-inferior to the efavirenz. 45 Even though both of the treatment regimens (raltegravir and efavirenz) were well tolerated, the subjects in raltegravir arm experienced significantly fewer drug related adverse events. Considering all the non-completers as the failures (NC = F), 75.4% (212/281) patients on raltegravir regimen achieved viral RNA level , 50 copies/ml. In comparison, among the patients receiving efavirenz, ∼68% (192/282) of the individuals achieved viral RNA level , 50 copies/ml. Similar results were reported at the 48 week and 96 week of the study duration. At 48 weeks, 86% of patients on raltegravir regimen compared to 82% receiving efavirenz had ,50 copies/ml HIV-1 RNA. 46 At 96 weeks, the viral suppression to ,50 copies/ml was 81% and 79%, respectively, in two arms of study. 47 In fact, raltegravir was superior to efavirenz (85% vs. 79%) in reducing the viral load to less than 50 copies/ml, when the 156 week analysis was performed considering only the treatment related discontinuations as failure. The number of patients who achieved ,400 copies/ml at 156 week of treatment was ∼80% and 72%, in raltegravir and efavirenz study groups, respectively. 45 Efficacy of raltegravir in patients infected with non-B subtype HIV-1 was evaluated in STARTMRK and BENCHMRK trials. 48 Non-B subtype HIV-1 infections account for approximately 90% of infections worldwide and is prevalent in developing countries like India, South Africa, and countries in Southern America. Subtype C alone is responsible for nearly 50% of all HIV-1 infections. Subtype B infections are prevalent in Europe and United States. After 96 week of raltegravir treatment in ART naïve patients, virologic, and immunologic response in non-B subtype patients was similar to subtype B patients with 95% and 89% of patients, respectively, achieved HIV-1 RNA level , 50 copies/ml. Similar efficacy of raltegravir in non B subtype was observed in treatment experienced patients in BENCHMRK studies. 48 A 96 week study to determine the efficacy and safety of 800 mg once-daily raltegravir dose compared to twice a day 400 mg raltegravir (ClinicalTrials.gov identifier NCT00745823) was carried out in treatment naïve patients. 49 This phase III clinical trial was multicenter, double blinded and randomized. Patients in both arms (400 mg raltegravir twice a day vs. 800 mg single dose) were also given a single dose of Truvada (200 mg of emtricitabine and 300 mg of tenofovir). In the patient group receiving 800 mg single dose, 83% (n = 318/382) of patients achieved HIV-1 RNA level ,50 copies/ml, compared to ∼89% (n = 343/386) in the group receiving 400 mg raltegravir twice a day. The differences between two dosage groups were more stark in patients with high viral load (.100,000 copies/ml of HIV-1 RNA). In these patients, only 74% (n = 113/152) of individuals in once-daily dose (800 mg) group achieved viral suppression compared to 84% of individuals in twicedaily dose group. Even though these results with once-daily dosage seem promising, it did not meet the pre-defined statistical criteria for non-inferiority. 49, 50 Based on these findings, Merck terminated the trial and the patients were switched to the approved twicedaily raltegravir dose.
Efficacy of raltegravir in combination with protease inhibitors darunavir and ritonavir (Table 1) in treatment naïve HIV-1 patients was determined in a phase 2b study. 51 The study was carried out to determine if these two classes of inhibitors were sufficient to control the HIV-1 infection and hence the patients will be spared of the potential severe toxicity associated with reverse transcriptase inhibitors. The enrolled patients were $18 years of age, with HIV-1 viral RNA load $5000 copies/ml, and contained no more than one darunavir resistance mutation or known raltegravir associated major resistance mutation in IN. Patients (n = 112) were given darunavir (two tablets of 400 mg), single 100 mg capsule of ritonavir, and the recommended twice a day dose (400 mg) of raltegravir. Darunavir/ritonavir in combination with raltegravir was well tolerated in patients. The primary end point was virologic failure at week 24 or earlier. The viral load was ,50 copies/ml in 79% and ,200 copies/ml in 93% of the patients at 24 week analysis using an intent to treat approach. At 24 weeks, 16% of patients had virologic failure and by week 48, virologic failure rate was 26%. The patients with a baseline viral load of more than 100,000 copies/ml and lower CD4 counts had a higher tendency to experience virologic failure (n = 18/43). In summary, even though the virologic efficacy observed in this study with darunavir/ritonavir in combination with raltegravir met the required protocol definition of being acceptable at 24 weeks but at 48 weeks only 71% of patients had less Clinical Medicine Reviews in Therapeutics 2012:4 than 50 copies/ml of HIV-1 RNA. 51 The unacceptably high virologic failure associated with patients with baseline viral load of .100,000 copies/ml might be due to presence of low level raltegravir resistance mutations in patients.
Final analysis of Protocol 004 (Merck) showed durable efficacy and tolerability of raltegravir in combination with tenofovir/lamivudine (300/300 mg single dose a day) in treatment naïve HIV-1 infected patients. 52 The patients enrolled in this study (ClinicalTrials.gov identifier-NCT00100048) had .5000 copies/ml of HIV-1 RNA, CD4 cells . 100 cells/mm 3 , and no prior resistance to the drugs used in the study. During the first 48 weeks, patients in one group (n = 160) were given different doses of raltegravir (100/200/400/600 mg twice a day) and the patients in another group (n = 38) received efavirenz. 53 All treatment groups showed significant rapid and durable improvement in their plasma HIV-1 RNA level with 83% to 88% of patients achieving ,50 copies/ml. Patients receiving raltegravir achieved RNA levels below the detection much faster than the patients on efavirenz therapy. In this study, raltegravir was well tolerated at all the doses. After 48 weeks, all patients in the raltegravir group received 400 mg twice a day. Similar efficacy and safety in the raltegravir arm of the study was reported at 96 week 54 and 192 week. 55 At 96 week, 83% of the patients in the raltegravir group and 84% in the efavirenz group achieved ,50 copies/ml HIV-1 RNA. At week 192, 74% of the patients in both groups (raltegravir vs. efavirenz) maintained ,50 copies/ml HIV-1 RNA.
Final analysis of this study at 240 week reported that patient group receiving raltegravir had a slightly higher percentage (69%) of people with ,50 copies/ml compared to efavirenz group (63%). The number of CD4 T-cells increased continuously during this study period. Exploratory analysis revealed a strong correlation between the baseline CD4 counts and log HIV-1 RNA decline at 8 week with the progressive increase in the CD4 cells over the duration of treatment. This finding also underscores the need to start the treatment early in HIV-1 infected individuals to have a better prognosis. Raltegravir was generally well tolerated for 5 years and was associated with fewer adverse events related to the treatment compared to efavirenz in combination with tenofovir/ lamivudine. 52 The frequent clinical adverse events associated with raltegravir therapy included nausea, dizziness, headache, diarrhea, vertigo, and fatigue. Patients on raltegravir regimen had minimal effects on LDL-cholesterol and triglycerides. Frequency of immune reconstitution inflammatory response (IRIS) in raltegravir treated group was similar to as in groups receiving other antiretroviral drugs. A long term safety profile of raltegravir and associated adverse events have been reviewed earlier. 56 Raltegravir is equally effective in a diverse cohort of patients. Safety and efficacy of raltegravir was determined in a clinical study which enrolled 74% of (156/209) HIV-1 infected black patients and 47% (98/209) females. Some of these individuals were ART naïve (n = 22), ART experienced with failing previous treatment (n = 98) and remaining were intolerant to current therapy (n = 89). Results reported after 48 weeks of treatment with raltegravir in combination of other approved ART drugs showed that 68% (98/145) of black patients and 78% (39/50) of non-black patients achieved HIV-1 RNA levels below 50 copies/ml. Similarly, 68% (61/90) of female patients compared to 72% (76/105) male patients achieved HIV-1 RNA level below 50 copies/ml. 43
Resistance to Raltegravir
Development of resistance to antiviral drugs seems to be an inevitable phenomenon due to high mutation rate in HIV-1 replication. 57 Treatment with raltegravir results in the emergence of resistant viruses containing mutations in IN, specifically in proximity to the active site. Raltegravir has a low genetic barrier; even a single mutation in IN results in marked reduction in virus susceptibility. In BENCHMRK 1 and BENCHMRK 2 studies, genotyping of IN in the patients experiencing virologic failure suggested two predominantly pathways associated with the presence of N155H or Q148H/R/K. 58 Often, the N155H pathway with the lower resistance is replaced by the Q148H/R/K pathway resulting in higher replication rate and significant reduction in the susceptibility to raltegravir. 59, 60 Substitution at Q148 resulted in more severe defect in replication 61 and IN activity compared to the mutations at N155. 19 In small populations, another pathway with Y143/C/H/R mutations was also observed. 58, 62 The level of resistance provided by mutations at Q148 and Y143 is always higher than N155 mutations. 63 These primary mutations are often associated with secondary mutations (N155H-E92Q, Q95K, T97A, Y143R/H, V151I, L74M, G163R; Q148H/R/K-G140S/A, E138K; Y143C/H/R-L74M, T97A, E138A/D, G163R, S230R) which provide much higher level of resistance and replication rate of mutant viruses. [64] [65] [66] [67] [68] [69] Primary resistance mutations and majority of secondary mutations do not result from the natural polymorphism in the raltegravir naïve patients. [69] [70] [71] The patients with higher baseline viral load were at greater risk of developing resistance to raltegravir. Several of these mutations provide cross-resistance to elvitegravir. It rules out the use of elvitegravir as salvage therapy in patients failing the raltegravir treatment. Fortunately, several of these mutant viruses are susceptible to dolutegravir (S/GSK134972), a second generation IN inhibitor. 72, 73 Moreover, these mutations in the active site of IN do not affect the susceptibility of the virus to other antiviral drugs like protease inhibitors, reverse transcriptase inhibitors and entry inhibitors (Table 1) . Hence, a combination therapy with drugs targeting multiple viral targets is always recommended.
Till now, the primary resistance mutations were not observed in IN STI naïve therapy patients; hence the existing treatment guidelines did not recommend an IN genotype before starting the raltegravir based treatment. 74 However, recently two reports have indicated the occurrence of transmitted resistance to raltegravir, one involving N155H mutation 75 and another patient with Q148H and G140S. 76 These mutations caused the raltegravir treatment failure in these patients. These cases illustrate the presence of multi-drug resistance even in treatment naïve patients and underscore the need to obtain the genotype present in individual and tailor the therapy accordingly.
Patient Preference
By virtue of being a recently approved drug for HIV-1 treatment, there are few clinical studies which have deciphered the patient preference for raltegravir compared to other drugs. However, raltegravir therapy is generally well-tolerated with significantly less severe adverse events compared to other available treatments. Patients who were on a stable efavirenz treatment for more than three years reported a better quality of life when they switched to raltegravir. 77 Adverse events associated with efavirenz include neuropsychiatric issues, depression, anxiety, and sleep problems. Patients who were switched to raltegravir reported significant improvements in anxiety and stress as well as their lipid profile. 77 The patients switched to raltegravir from a tenofovir/ emtricitabine and ritonavir boosted protease inhibitor treatment reported improvement in the renal function, increased glomerular filtration rate and a drop in the urine protein level. 78 In patients with multidrugresistant HIV-1 infection under control (viral RNA level , 400 copies/ml), a switch from fusion inhibitor enfuvirtide based regimen to raltegravir (400 mg twice daily) in combination with same background regimen was well tolerated and had sustained antiviral efficacy for up to 48 weeks. 79 Out of the total 85 patients who had switched to raltegravir based regimen, only one experienced virologic failure and none of the patients were lost in follow up or died.
In SWITCHMRK1 and 2 studies, patients on lopinavir/ritonavir (Kaletra) therapy who had HIV-1 replication in control and viral RNA level , 75 copies/ml for three months were switched to raltegravir. 81 Both groups also continued background therapy of at least two nucleoside or non-nucleoside reverse transcriptase inhibitors. Lopinavir/ritonavir (Kaletra) therapy can cause lipid abnormalities in patients. 80 At 12 week analysis after switching to raltegravir, patients had greater reduction in baseline fasting cholesterol and triglycerides compared to the patients continuing the lopinavir/ritonavir (Kaletra) regimen. However, the virological efficacy analyses after 24 week of treatment did not establish the non-inferiority of raltegravir to lopinavir/ritonavir (Kaletra) and hence the study was stopped. 81 In this study, patients were not tested for resistance because all the enrolled patients needed to meet undetectable viral load. It highlights the need to have the information about previous treatment and possible resistance mutations in the viral population. ART naïve patients receiving raltegravir in combination with lopinavir/ritonavir (Kaletra) had less severe effect on bone density compared to traditional antiretroviral regimen-emtricitabine/ tenofovir (Truvada) and lopinavir/ritonavir (Kaletra). Both of these treatment regimens had similar antiviral efficacy over 96 weeks of therapy. 82 At 48 weeks, patients switching from ritonavir boosted protease inhibitors to raltegravir (SPIRAL study) with combination therapy experienced similar efficacy, better lipid profile and lower total to HDL ratios than continuing the ritonavir boosted protease inhibitor. 83 Ritonavir boosted protease inhibitor therapy is associated with an increased risk of myocardial infarcation caused by dyslipidemia. In HIV-1 uninfected individuals, raltegravir (400 mg twice a day) induced much less postprandial (after meal) lipid changes compared to the low dose of ritonavir (100 mg once a day). 84 In summary, generally the patients switching to raltegravir based treatment from most other regimens observed similar potent antiviral efficacy with an added advantage of less severe adverse events.
Place in Therapy
Guidelines issued by Department of Health and Human Services (DHHS) in 2011 recommends four preferred regimens for the treatment of HIV/ AIDS in ART naïve patients. 74, 85 These guidelines advocate earlier initiation of ART to reduce both AIDS related and non-related morbidity and mortality and the prevention of sexual transmission of HIV-1. These regimens were proposed on the basis of randomized controlled trials, efficacy, and safety of drugs. A list of all of the FDA approved drugs for HIV-1 treatment is given in Table 1 . Each of these regimens include drugs targeting (i) reverse transcriptase-(NRTIs, Nucleoside reverse transcriptase inhibitors; NNRTIs, Non-nucleoside reverse transcriptase inhibitors)-efavirenz/tenofovir/emtricitabine, (ii) protease-atazanavir/ritonavir (ATV/r) in combination with NRTIs, (iii) protease-darunavir/ ritonavir (DRV/r) in combination with NRTIs tenofovir/emtricitabine, and (iv) IN-raltegravir in combination with NRTIs tenofovir/emtricitabine. Initially, raltegravir was approved to use in treatment experienced HIV-1 infected individuals with multidrug resistance and in patients as salvage therapy. In 2009, FDA approved raltegravir for use in treatment naïve patients. Raltegravir in combination with NRTIs, abacavir or zidovudine, and lamivudine is also an acceptable regimen for ART naïve patients. In a pilot study, raltegravir (400 mg twice a day) in combination with abacavir/ lamivudine (600/300 mg once a day) was effective and well tolerated with no serious adverse events during the 48 week of the treatment regimen. 86 Advantage of raltegravir in comparison to other drugs is its tolerability and fewer serious adverse events related to the drug. Since, raltegravir is not metabolized by liver CYP enzymes, but rather via UGT1A1 mediated glucuronidation, it has very few interactions with other antiretroviral drugs. In patients with mild to moderate hepatic or renal insufficiency, no dosage adjustment of raltegravir was required. Compared to other treatment plans, raltegravir based therapy has certain limitations; raltegravir must be administered twice a day. It would restrict its use as in a "QUAD like" drug having a combination of drugs and once a day dosing. A single-tablet once a day dose of combination drug "QUAD" containing IN inhibitor elvitegravir, CYP3A inhibitor and pharmacokinetic booster cobicistat, reverse transcriptase inhibitors emtricitabine and tenofovir showed non-inferiority to Atripla (efavirenz, emtricitabine and tenofovir) in treatment naïve patients (ClinicalTrials.gov identifier NCT01095796). A low genetic barrier to raltegravir resistance is another risk, a single mutation in IN can render raltegravir largely ineffective. Clinical studies involving raltegravir in combination with other classes of approved HIV-1 drugs are ongoing and should result in an increase in approved regimens utilizing raltegravir.
Patients on effective ART have residual plasma viremia which may be due to low-level replication or release of virus from long-lived HIV-1 infected cells. Efforts have been made to add another drug to existing effective regimens in patients to lower the residual viremia. Raltegravir intensification in several studies where patients were on optimized therapy with controlled viral replication did not further reduce the HIV-1 RNA level in plasma [87] [88] [89] [90] [91] or in cerebrospinal fluid. 92 Some studies have indicated that raltegravir intensification results in a specific and transient increase in episomal 2-LTR circles and immune activation which, however, normalized to the baseline level over longer (beyond 4 week) period of treatment 93 and a decrease in unspliced HIV-1 RNA level in CD4 cells from ileum. 90 The results from majority of studies suggest that low level plasma viremia is not due to ongoing viral replication and eradication of HIV-1 will require novel therapeutic approaches.
Conclusions
Raltegravir belongs to an important new class of antiretroviral drugs which inhibits IN. Raltegravir has proved to be safe and effective in treatment naïve as well as treatment experienced patients failing the existing antiretroviral regimens. However, raltegravir is not without its own drawbacks, foremost is its low genetic barrier resulting in development of resistance. Several IN inhibitors with a longer dissociation rate have shown promise in being effective against the emerging raltegravir resistant viruses. 4, 5 Efforts to target IN oligomerization with small molecule inhibitors, 3′-OH processing, and novel pharmacophores to inhibit the strand transfer are ongoing. The need to develop antiretroviral agents with novel mechanism of action persists for treatment in naïve and experienced patients. It is especially crucial to target and eliminate the viral reservoirs in HIV-1 latently infected cells to eradicate viral infection. Along with the better education to control the HIV-1 transmission and the continued improvement in the treatment regimens, we can hope a better outcome for HIV-1 patients. It may be interesting to identify novel targets for therapy or vaccines by taking cues from the "elite controllers", HIV-1 infected people some of whom control their viremia to low levels and do not develop AIDS. 94 Teaching the immune system to control the HIV-1 replication might be a better choice than life-long treatment with antiretroviral drugs.
